ChristopherCharlesDeRenzoMD

Pediatric Hematology & Oncology • Memphis, TN

Pediatric Solid Tumor Oncology

Assistant Member, Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital

Join to view full profile

Dr. DeRenzo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. DeRenzo's full profile

Already have an account?

Office
262 Danny Thomas Pl
Memphis, TN 38105
Phone+1 901-595-3300

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2011 - 2014
Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 2008 - 2011
Rutgers Robert Wood Johnson Medical SchoolClass of 2008

Certifications & Licensure

TN State Medical License 2018 - 2025
TX State Medical License 2014 - 2020
OH State Medical License 2008 - 2012
UT State Medical License 2011 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

7 citations
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Meenakshi Hegde, Shoba Navai, Christopher DeRenzo, Sujith K Joseph, Khaled Sanber
Nature Cancer. 2024-06-01
A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target c...
Ha Won Lee, Carla O'Reilly, Alex N Beckett, Duane G Currier, Taosheng Chen
Journal of Experimental & Clinical Cancer Research. 2024-04-01
15 citations
CD47 expression is critical for CAR T-cell survival in vivo.
Alex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Phuong Nguyen, Peter Vogel
Journal for Immunotherapy of Cancer. 2023-03-01

Press Mentions

Improved CAR T Cell Homing Increases Efficacy of Osteosarcoma TreatmentAugust 8th, 2024
Improved Chemokine Homing Enhances CAR T--Cell Therapy for OsteosarcomaAugust 8th, 2024
Improved Chemokine Homing Enhances CAR T-cell Therapy in Preclinicals for OsteosarcomaAugust 8th, 2024